NCT05603910 is a Phase 1 clinical trial of Lenvatinib in Recurrent Endometrial Carcinoma, sponsored by Aaron Wolfson.

Who is sponsoring NCT05603910?

NCT05603910 is sponsored by Aaron Wolfson.

What drugs are being tested in NCT05603910?

Interventions in NCT05603910: Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy.

What condition does NCT05603910 study?

NCT05603910 studies Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma.

Is NCT05603910 still recruiting?

NCT05603910 is currently recruiting now. Last updated 24 February 2026.

Last reviewed 2026-02-24 · How we verify

NCT05603910

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Recruiting now Phase 1 Last updated 24 February 2026

What this trial tests

Phase 1 trial testing Lenvatinib in Recurrent Endometrial Carcinoma in 18 participants. Currently enrolling.

Timeline

15 April 2023

Primary endpoint
15 April 2027

15 April 2030

Quick facts

Lead sponsor	Aaron Wolfson
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	15 April 2023
Primary completion	15 April 2027
Estimated completion	15 April 2030
Sites	1 location across United States

Drugs / interventions tested

Lenvatinib (LENVATINIB) — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →
Hypofractionated External Beam Radiation Therapy

Conditions studied

Recurrent Endometrial Carcinoma — all drugs for Recurrent Endometrial Carcinoma →
Unresectable Endometrial Carcinoma — all drugs for Unresectable Endometrial Carcinoma →

Sponsor

Aaron Wolfson

Who can join

18 and older, female only, with Recurrent Endometrial Carcinoma or Unresectable Endometrial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation therapy, to support cancer cells in multiplying and spreading to other body sites.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.
El-Ghazzi N, Durando X, Giro A, Herrmann T. · · 2023 · cited 12× · PMID 37288137 · DOI 10.2147/ott.s368050
Drug discovery in advanced and recurrent endometrial cancer: Recent advances.
Francoeur AA, Ayoub N, Greenberg D, Tewari KS. · · 2025 · cited 4× · PMID 40612873 · DOI 10.32604/or.2025.061120

Verify or expand the search:

Other trials of Lenvatinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
NCT07493668 — Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · Phase 2 · not yet recruiting

Other recruiting trials for Recurrent Endometrial Carcinoma

Currently open trials in the same condition.

NCT07198074 — Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With · Phase 3 · recruiting
NCT06518564 — Avelumab and M1774 in ARID1A-mutated Endometrial Cancer · Phase 2 · recruiting
NCT05950464 — Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo · Phase 1 · recruiting
NCT05691504 — Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers · Phase 1 · active not recruiting
NCT05554328 — Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway M · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05603910 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aaron Wolfson
Last refreshed: 24 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05603910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing